Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

The firm recorded $58 million in sales for the autologous TIL therapy, which it is working on moving into earlier melanoma settings and other tumor types.

The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

Genetic testing could improve cancer outcomes for patients, but historical research abuses and access issues have slowed ...

The funding is to go toward the launch of the Elephas Live Platform as a laboratory-developed test to predict immunotherapy response.

Under the agreement, Singapore-headquartered ImmunoScape will develop what it calls a "Seed-and-Boost" immunotherapy, combining its T-cell receptor therapies (the "seed") followed by Cue's IL-2-based ...

DMT in recent months has focused resources on developing its lead gene therapy candidate 4D-150 in wet age-related macular degeneration.

The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

The firm had decreased Q3 sales for precision oncology drugs including Ibrance, Tukysa, and Bosulif, but sales increased for ...

Researchers presented new data on Phenomix Sciences' genetic risk scores at the Obesity Society's ObesityWeek conference.

Atara transferred the BLA to Pierre Fabre, which already handles manufacturing, regulatory, and commercial activities for Ebvallo in Europe.